Boston Scientific Sees Grim Q2 But Eyes Growth By Q4 Fueled By Product Launches

The big news at Boston Scientific's first-quarter earnings call was how badly the pandemic had impacted the second quarter so far, with sales down almost $500m in April. But the company said it already saw signs that procedure volumes were beginning to bounce back.